智通财经APP讯， 北芯生命(688712.SH)发布2025年度业绩快报，报告期内，公司实现营业收入 54,210.81万元，较上年同期增长71.23%;归属于母公司所有者的净利润8,062.19万元，归属于母公司所有 者的扣除非经常性损益的净利润6,513.95万元，较上年同期实现扭亏为盈。 报告期内，公司核心产品凭借有显著临床价值的差异化创新，在满足过往未被完全满足的重要临床需求 方面，持续获得国内外专家的广泛认可，产品已进入全球超过60个国家和地区，在超过2,000家医院实 现临床应用。其中，海外业务营业收入同比增长超过130%，在公司收入占比进一步提升，公司国际化 业务取得快速突破。 ...

证券日报网讯 2月27日，北芯生命发布公告称，公司2025年实现营业总收入54210.81万元，同比增长 71.23%；归属于母公司所有者的净利润8062.19万元。 （文章来源：证券日报） ...

格隆汇2月27日丨北芯生命(688712.SH)公布2025年度业绩快报，报告期内，公司实现营业收入5.42亿 元，较上年同期增长71.23%；归属于母公司所有者的净利润8062.19万元，归属于母公司所有者的扣除 非经常性损益的净利润6513.95万元，较上年同期实现扭亏为盈。报告期末，公司财务状况良好，总资 产9.46亿元，较报告期初增长20.77%。 报告期内，公司核心产品凭借有显著临床价值的差异化创新，在满足过往未被完全满足的重要临床需求 方面，持续获得国内外专家的广泛认可，产品已进入全球超过60个国家和地区，在超过2000家医院实现 临床应用。其中，海外业务营业收入同比增长超过130%，在公司收入占比进一步提升，公司国际化业 务取得快速突破。 公司一方面持续加码研发创新，尤其在智能化、精准化介入治疗的前沿领域，坚持做底层的设计与技术 创新。围绕心血管疾病的精准诊疗领域，公司在研管线稳步推进，为中长期可持续发展注入新动能。另 一方面，公司不断构建卓越的组织能力和运营能力，持续完善治理结构。随着主营业务收入规模快速扩 大，期间费用率得到有效控制。报告期内，归属于母公司所有者的净利润、归属于母公司所有者的 ...

单位：人民币 万元 证券代码：688712 证券简称：北芯生命 公告编号：2026-001 深圳北芯生命科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载深圳北芯生命科技股份有限公司（以下简称"公司"）2025年 度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(％) | | --- | --- | --- | --- | | 营业总收入 | 54,210.81 | 31,660.43 | 71.23 | | 营业利润 | 8,906.80 | -6,079.16 | 不适用 | | 利润总额 | 8,882.87 | -6,092.27 | 不适用 | | 归属于母公司所有者的净利润 | 8,062.19 | -4,359.62 | 不适用 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 6,513 ...

南财智讯2月27日电，北芯生命发布2025年度业绩快报，报告期内公司实现营业收入5.42亿元，同比增 长71.23%；归属于上市公司股东的净利润8062.19万元，同比扭亏；基本每股收益0.22元，同比扭亏。 ...

新股现在俨然已经成了刺客，成了割韭菜的利器，上市之后，连续下跌，跌一天，割一刀，一刀一刀的在收割韭菜，你敢相信，一只新股上市7天连续跌 了6天，从55元跌到39元，从K线上看，全部都是阴线，连续7根阴线，再跌下去，公司都快卖给散户了！ 在询价之后，中金公司跟北芯生命商量，把价格定在了17.52元，发行5700万股，实际募集8.99亿，中金公司拿走了7300万左右的保荐费！ 还是保荐费赚的容易，中金公司拿了7300万的保荐费，拍拍屁屁走人了，留下了一堆烂摊子，看看北芯生命上市之后的表现！ 那么这是哪只股票？公司主要是做什么的？公司业绩怎么样？保荐机构是哪家？我们一起来看看！ 这只股票就是688712北芯生命！ 北芯生命是专注心血管疾病精准诊疗创新医疗器械研发的国家高新技术企业，核心产品为IVUS（血管内超声）系统和FFR（血流储备分数）系统，是国 内首家拥有这两类产品组合的国产企业，填补国内空白并降低进口依赖！ 通过北芯生命的财务数据可以看到，公司2022-2024年，营收分别为9245万元、1.840亿元、3.166亿元，净利润分别为-2.9亿元、-1.398亿元、-4360万元， 可以看到北芯生命这几年一直 ...

Core Insights - The A-share market has welcomed 16 new listings since 2026, with four medical device companies standing out as a highlight of the new year [1] - The newly listed medical device companies have shown impressive first-day performance, with all four stocks rising over 170% on their debut [1][3] - The strong stock performance is supported by positive earnings forecasts, with all four companies expected to report growth in 2025 [1][5] Group 1: Market Performance - The four medical device stocks, including Beixin Life, Haiseng Medical, Aide Technology, and Aishalen, experienced significant first-day gains, with Beixin Life rising by 183.33% on its debut [3] - As of February 13, the stock prices for these companies ranged from 18.77 yuan to 39.48 yuan, with total market capitalizations between 22.17 billion and 164.6 billion yuan [3] - The medical device sector is currently in a high-growth cycle, attracting significant capital market attention [7] Group 2: Company Performance and Projections - Beixin Life, which focuses on cardiovascular disease diagnostic devices, is projected to turn a profit in 2025, with expected revenues between 520 million and 560 million yuan, representing a growth of 64.24% to 76.88% [6] - Haiseng Medical anticipates a revenue of 345 million yuan in 2025, a year-on-year increase of 13.68%, while Aide Technology expects approximately 302 million yuan, up 9.74% [6] - Aishalen forecasts revenues between 890 million and 940 million yuan, with a growth rate of 28.65% to 35.89% due to increased demand and expanded production capacity [6] Group 3: Industry Trends and Future Prospects - The medical device IPO trend continues, with several companies, including Guangdong Boma Medical Technology, in the pipeline for listing [8] - Companies like Core Medical and Tongxin Medical are also vying to become the first domestic artificial heart stock, despite not yet being profitable [9] - The medical device sector is shifting from "concept speculation" to "performance-driven" investments, emphasizing the importance of technological originality and profitability [9]

Core Viewpoint - Beixin Life Technology Co., Ltd. has successfully listed on the STAR Market, marking a significant milestone as the first medical device company in the cardiovascular field to do so since 2024, breaking the long-standing monopoly of foreign giants in the high-end interventional medical device sector [1] Group 1: Market Opportunity and Product Innovation - Cardiovascular diseases are a leading health threat globally, with 330 million patients in China, including approximately 11.39 million with coronary heart disease, indicating a rising prevalence [2] - The company focuses on addressing critical clinical pain points in cardiovascular diagnosis and treatment, having developed innovative solutions such as the Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) systems, which enhance the precision of coronary interventions [2][3] - The IVUS system is the first domestically approved high-definition product, while the FFR system is recognized as a "gold standard" for coronary heart disease diagnosis, significantly reducing patient burden and improving treatment accuracy [3] Group 2: Research and Development Strength - The company has invested 438 million yuan in R&D from 2022 to June 2025, with a projected R&D expense ratio of 35.65% in 2024, surpassing industry averages [4] - Beixin Life has secured 185 domestic and international patents, including 86 invention patents, covering key technologies in ultrasound transducers and image algorithms [4] Group 3: Product Portfolio and Market Penetration - The company has developed a comprehensive product ecosystem covering diagnostic devices, therapeutic instruments, and supporting consumables, enhancing procurement stickiness for hospitals [5] - As of September 2025, Beixin Life's products are available in 30 provinces and approximately 1,000 hospitals in China, with over 70% being tertiary hospitals [7] Group 4: Financial Performance and Growth - The company's revenue surged from 92.45 million yuan in 2022 to 317 million yuan in 2024, representing a growth of over 340%, with a year-on-year increase of 71.29% in 2024 [7] - Despite price pressures from centralized procurement, the company maintained a gross margin of 63.32% in 2024, demonstrating resilience and effective cost control [10] Group 5: Industry Trends and Future Outlook - The cardiovascular interventional device market is projected to grow significantly, driven by an aging population and supportive policies, with the precision PCI market expected to expand from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, at a CAGR of approximately 21.1% [11] - The penetration rates for FFR and IVUS in China are currently low, at 3.4% and under 5% respectively, indicating substantial growth potential as clinical awareness increases and domestic product prices decrease [13] - Beixin Life aims to leverage its first-mover advantage in the domestic market and its CE MDR certification to capture a larger share of the global cardiovascular interventional device market [17][19]

Core Insights - The article emphasizes the importance of technological self-reliance and innovation as key drivers for building a modern socialist country, as highlighted by national leaders during their first local inspection in the "14th Five-Year Plan" period [1] - The FOF ecosystem of Kunyuan Asset is accelerating its IPO activities, with two significant companies, Beixin Life (688712.SH) and Aixin Yuanzhi (00600.HK), successfully listing on the stock exchanges within a short span of six days, marking a strong start for the year [1][4] Company Highlights - Beixin Life (688712.SH) is recognized as the first domestic company to focus on intelligent and precise intervention in cardiovascular diseases, successfully listing on the Sci-Tech Innovation Board and achieving multiple industry milestones [4][6] - Aixin Yuanzhi (00600.HK) specializes in AI visual chip design and has become a leading player in the high-end AI chip market, successfully listing on the Hong Kong Stock Exchange [7][10] Market Trends - The article discusses the strategic focus on future industries such as quantum technology, biomanufacturing, and AI, which are identified as new economic growth points in the "14th Five-Year Plan" [4] - The successful IPOs of Beixin Life and Aixin Yuanzhi reflect the growing trend of domestic high-end medical devices and AI chips, indicating a shift from import substitution to original technology-driven innovation [5][10] Investment Strategy - Kunyuan Asset's FOF ecosystem aims to support high-quality tech companies through early-stage investments, alleviating financial pressures and allowing firms to focus on core technological innovations [9] - The article highlights the importance of capital market development in supporting the growth of tech enterprises, aligning with national strategies for economic and social development [8][10]

Group 1 - The core point of the article is that Beixin Life (688712.SH) experienced a significant drop in stock price, closing at 41.84 yuan, a decrease of 6.67%, and hitting a new low since its listing [1] - Beixin Life was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, issuing 57 million shares, which accounts for 13.67% of the total share capital post-issuance, at a price of 17.52 yuan per share [1] - The total amount raised from the issuance was 998.64 million yuan, with a net amount of 898.89 million yuan after deducting issuance costs, which was 53.32 million yuan less than the original plan [1] Group 2 - The funds raised are intended for the construction of an interventional medical device industrialization base, research and development projects for interventional medical devices, and to supplement working capital [1] - The total issuance costs for Beixin Life's public offering amounted to 99.75 million yuan (excluding VAT), with underwriting and sponsorship fees accounting for 73.00 million yuan [1]